Is The Aaron's Company, Inc. (AAN) a Buy, Sell, or Hold?
NYSE : AAN
The Aaron's Company, Inc.
$10.09 USD
$0.1 (1.0%)
- Volume
- 2.78M
- Average Volume
- 1.05M
- Market Capitalization
- $318.35M
- P/E Ratio
- 112.11
- Dividend Yield
- 4.96%
- Price Target
- $10.10
- Year High
- $11.90
- Year Low
- $6.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $5.31
- Current Ratio
- $2.08
Company Overview
NYSE
Douglas A. Lindsay
Rental & Leasing Services
Industrials
AAN
9071
US
USD
Liquidity Metrics
0.84
2.08
0.37
0.14
5.31
Sales & Valuation
$2.14B
0.15
0.45
3.70
2.79
Profitability
$0.09
$2.82M
0.13%
-0.05%
0.41%
0.15%
P/E Metrics
112.11
-0.23
-0.23
Analyst Price Target & Rating
$10.10
$19.00
$10.00
0/5
19 Analysts
-0.10%
Poll Results
About The Aaron's Company, Inc. (NYSE:AAN) Stock
The Aaron's Company, Inc. provides flexible acquisition options, allowing consumers to either lease-to-own or directly purchase a variety of goods. The company serves customers across the United States and Canada by distributing furniture, major appliances, electronics, computers, and related accessories through its corporate-owned stores, independently operated franchised outlets, and a robust e-commerce platform. Additionally, Aaron's is involved in the manufacturing and supply of bedding and upholstered furniture. As of December 31, 2021, the firm's retail network included 1,074 company-operated stores and 236 franchised locations. Founded in 1955 under its previous name, Aaron's SpinCo, Inc., the enterprise is currently headquartered in Atlanta, Georgia. ...
2026-04-21 18:45:00
Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies – outcomes not previously observed in SPS
2026-04-21 07:00:00
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. These findings, which will be presented today at the 2026 American Academy of Neurology (AAN) annual meeting, build on previously reported positive topline data and provide.
2026-04-20 08:00:00
100% of patients achieved rapid, sustained improvements across MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial
2026-04-19 18:00:00
VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.
2026-04-18 01:00:00
ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease symptoms in this underserved patient population ADAPT SERON, OCULUS, and Jr study results build on VYVGART's approved gMG indication and show its potential as the first and only biologic therapy effective across MG subtypes ADHERE post hoc analysis supports earlier use of VYVGART in treatment-naïve CIDP patients, with 87.5% achieving early benefit April 18, 2026, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the presentation of new data for VYVGART® (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) in myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP) at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago from April 18-22, 2026. Presentations will also highlight new data for adimanebart in congenital myasthenic syndromes (CMS) and argenx's broader neuromuscular pipeline, including Phase 3 programs evaluating empasiprubart in CIDP.
2026-04-17 09:05:00
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18–22, 2026 in Chicago, IL. The Company will present real-world data from a sub-group analysis of the ongoing, Phase 4, prospective, observational, open-label LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults w.
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
2026-04-17 08:00:00
Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP
Frequently Asked Questions
-
What is the current The Aaron's Company, Inc. (AAN) stock price?
-
The Aaron's Company, Inc.(NYSE:AAN) stock price is $10.09 in the last trading session. During the trading session, AAN stock reached the peak price of $11.9 while $6.622 was the lowest point it dropped to. The percentage change in AAN stock occurred in the recent session was 1.0% while the dollar amount for the price change in AAN stock was $0.1.
-
AAN's industry and sector of operation?
-
The NYSE listed AAN is part of Rental & Leasing Services industry that operates in the broader Industrials sector.
-
Who are the executives of AAN?
-
Rachel G. George | EVice President, General Counsel, Secretary, Chief Compliance Officer & Chief Corporate Affairs Officer
Douglass L. Noe | Principal Accounting Officer, Vice President & Corporate Controller
C. Kelly Wall | Executive Vice President & Chief Financial Officer
Russell S. Falkenstein | Executive Vice President & Chief Operating Officer of Lease-to-Own
Douglas A. Lindsay | Chief Executive Officer & Director -
How many employees does AAN have?
-
Number of AAN employees currently stands at 9071. AAN operates from 400 Galleria Parkway SE, Atlanta, GA 30339-3182, US.
-
Link for AAN official website?
-
Official Website of AAN is: https://www.aarons.com
-
How do I contact AAN?
-
AAN could be contacted at phone #678 402 3000 and can also be accessed through its website. AAN operates from 400 Galleria Parkway SE, Atlanta, GA 30339-3182, US.
-
How many shares of AAN are traded daily?
-
The average number of AAN shares traded daily for last 3 months was 1.05M.
-
What is the market cap of AAN currently?
-
The market value of AAN currently stands at $318.35M with its latest stock price at $10.09